ND

Nathan Dau

Passaic Capital Management at Millennium

San Francisco Bay Area

Overview

Work Experience

  • Head of Private Investments, Passaic Capital Management

    2024 - Current

    Investing in innovative, fast growing private companies.

  • Executive Director

    2017 - 2024

    Focused on making growth equity and private equity investments in commercial stage healthcare companies. Target sectors include pharma services, medtech, health tech, dx/tools and synthetic biology. Lead or co-lead investor on all deals. Notable investments include Surgical Specialties (sold to GTCR), Preventice (sold to Boston Scientific), PatientPop (merger with Kareo to form Tebra), Seran Biosciences, Scientia, Histowiz, InBrace, Aerobiotix, Amyris, and Sera Prognostics (IPO).

  • Senior Associate

    2015 - 2017

    Growth equity investments in enterprise software companies.

  • Associate

    2012 - 2015

    Advised on over $28 billion of M&A transactions. Deals included sell-side and buy-side M&A and leveraged buyouts across multiple sectors including energy, industrials, homebuilding, media, and technology. Led the preparation of financial models and valuation analyses. Advised clients on M&A opportunities, capital allocation strategy, and PE investor exit scenarios.

  • Associate

    2006 - 2010

    Represented targets and acquirers in connection with seven M&A transactions with an aggregate deal value of over $2.2 billion. Advised issuers in connection with three IPOs, raising over $730 million of aggregate capital, and advised clients on debt offerings and private placements, raising over $2.5 billion of proceeds.

Relevant Websites